Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | AOC2 | O75106 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419305 | 0.85 | AOC3 (0.78) | AOC3TAAR1ALDH1A1RECQLKCNA3 | |
| SCHEMBL419306 | 0.85 | AOC3 (0.78) | AOC3TAAR1ALDH1A1RECQLKCNA3 | |
| SCHEMBL3983710 | 0.80 | AOC3 (1.00) | AOC3TAAR1ALDH1A1RECQLKCNA3 | |
| SCHEMBL3983712 | 0.80 | AOC3 (1.00) | AOC3TAAR1ALDH1A1RECQLKCNA3 | |
| SCHEMBL7258669 | 0.78 | LTA4H (0.44) | AOC3LTA4H | |
| SCHEMBL10477050 | 0.77 | AOC3 (0.61) | AOC3TAAR1ALDH1A1RECQLKCNA3 | |
| SCHEMBL6417265 | 0.77 | AOC3 (0.61) | AOC3TAAR1ALDH1A1RECQLKCNA3 | |
| SCHEMBL19784339 | 0.77 | AOC3 (0.67) | AOC3TAAR1ALDH1A1RECQLKCNA3 | |
| SCHEMBL2167367 | 0.77 | AOC3 (0.61) | AOC3TAAR1ALDH1A1RECQLKCNA3 | |
| SCHEMBL5576566 | 0.77 | AOC3 (0.61) | AOC3TAAR1ALDH1A1RECQLKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| US-9980928-B2 | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives | PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) | 2018-05-29 | — | — | US | disclosed |
| US-9980928-B2 | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives | PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) | 2018-05-29 | — | — | US | disclosed |
| US-9980928-B2 | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives | PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) | 2018-05-29 | — | — | US | disclosed |
| US-20170239197-A1 | HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES | PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) | 2017-08-24 | — | — | US | disclosed |
| US-20170239197-A1 | HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES | PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) | 2017-08-24 | — | — | US | disclosed |
| US-20170239197-A1 | HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES | PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) | 2017-08-24 | — | — | US | disclosed |
| US-9624158-B2 | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives | PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) | 2017-04-18 | — | — | US | disclosed |
| US-9624158-B2 | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives | PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) | 2017-04-18 | — | — | US | disclosed |
| EP-2945702-B1 | HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES | PROUS INST FOR BIOMEDICAL RES S A (ES) | 2017-01-11 | — | — | EP | disclosed |
| EP-2945702-A1 | HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES | Prous Institute for Biomedical Research, S.A. (ES) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014096377-A1 | HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES | PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014096377-A1 | HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES | PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) | 2014-06-26 | — | — | WO | disclosed |
| EP-2745876-A1 | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives | Prous Institute for Biomedical Research, S.A. (ES) | 2014-06-25 | — | — | EP | disclosed |
| EP-2745876-A1 | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives | Prous Institute for Biomedical Research, S.A. (ES) | 2014-06-25 | — | — | EP | disclosed |
| EP-2745876-A1 | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives | Prous Institute for Biomedical Research, S.A. (ES) | 2014-06-25 | — | — | EP | disclosed |
| EP-0888331-A4 | SYNTHESIS OF 3-[4-(2-AMINOETHOXY)-BENZOYL]-2-ARYL-6-HYDROXY-BENZO[b]THIOPHENES | LILLY CO ELI (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6008377-A | ACYLATING A N-DISUBSTITUED-PHENYLOXYETHYLAMINE CHLORO OR BROMO SALT WITH A BENZOTHIOPHENE DERIVATIVE IN PRESENCE OF TRIBOROCHLORIDE OR BROMIDE, DEALKYLATING ONE OR MORE PHENOLIC GROUP OF THE PRODUCT WITH ADDITIONAL BOROHALIDE | ELI LILLY AND COMPANY (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0888331-A1 | SYNTHESIS OF 3-[4-(2-AMINOETHOXY)-BENZOYL]-2-ARYL-6-HYDROXY-BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034888-A1 | SYNTHESIS OF 3-[4-(2-AMINOETHOXY)-BENZOYL]-2-ARYL-6-HYDROXY-BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239197-A1 | HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES | SLC1A2, PNMT, DBH | AOC3 1498/4885TAAR1 163/4885ALDH1A1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.